Camelia

Objective

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long- term Treatment with BELVIQ (lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects with Cardiovascular Disease or Multiple Cardiovascular Risk Factors. The main purpose of this research study is to assess whether lorcaserin HCl (brand name BELVIQ®) affects the risk of developing cardiovascular diseases in men and women at higher risk of developing these diseases.

Location:

Essentia Health Duluth

Disclosures:

None

For more information about a financial conflict of interest (FCOI), review the Essentia Health FCOI policy.

Last Updated: 06/19/2018

Research Study Categories

  • Adult Studies

Specialty

  • Cardiology
Contact
Clinical Trials at 866-839-4128
or clinicaltrials@eirh.org